Brief: Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-Dees
12/01/2026 13:09
Jan 12 (Reuters) - Praxis Precision Medicines Inc PRAX.O: PRAXIS PRECISION MEDICINES INC - TWO NDA SUBMISSIONS EXPECTED BY MID-FEB 2026 FOR ULIXACALTAMIDE IN ESSENTIAL TREMOR & RELUTRIGINE IN SCN2A/8A-DEES Source text: ID:nGNXhFgZr Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87